Compare · NTRA vs UNH
NTRA vs UNH
Side-by-side comparison of Natera Inc. (NTRA) and UnitedHealth Group Incorporated (UNH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and UNH operate in Medical Specialities (Health Care), so they compete in similar markets.
- UNH is the larger of the two at $386.95B, about 10.0x NTRA ($38.87B).
- Over the past year, NTRA is up 93.0% and UNH is up 51.0% - NTRA leads by 42.0 points.
- NTRA has been more active in the news (19 items in the past 4 weeks vs 13 for UNH).
- Both have 25 recent analyst ratings on file.
- Company
- Natera Inc.
- UnitedHealth Group Incorporated
- Price
- $271.44+0.55%
- $426.06+0.66%
- Market cap
- $38.87B
- $386.95B
- 1M return
- +23.26%
- +4.44%
- 1Y return
- +93.02%
- +51.02%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 19
- 13
- Recent ratings
- 25
- 25
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
Latest NTRA
- Director Chapman Rowan E sold $37,101 worth of shares (135 units at $274.82) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 4,663 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $410,825 worth of shares (1,500 units at $273.88) as part of a pre-agreed trading plan (SEC Form 4)
- Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
- CO-FOUNDER Sheena Jonathan sold $836,898 worth of shares (3,150 units at $265.68) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 246,202 units (SEC Form 4)
- Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $280,000 worth of shares (1,000 units at $280.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel sold $4,574,431 worth of shares (16,800 units at $272.29) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 172,294 units (SEC Form 4)
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $818,710 worth of shares (3,000 units at $272.90) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 134,643 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update
- Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
Latest UNH
- UnitedHealth upgraded by Robert W. Baird with a new price target
- UnitedHealth Group Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- UnitedHealth Group Reports Second Quarter 2026 Results
- UnitedHealthcare Launches New Spending Account Benefit, Putting More Choice in the Hands of Consumers
- Director Noseworthy John H was granted 206 shares, increasing direct ownership by 3% to 7,616 units (SEC Form 4)
- Director Montgomery Rice Valerie Md was granted 220 shares, increasing direct ownership by 3% to 7,876 units (SEC Form 4)
- Director Mcnabb Frederick William Iii was granted 250 shares, increasing direct ownership by 2% to 15,462 units (SEC Form 4)
- Director Gottlieb Scott was granted 210 shares, increasing direct ownership by 47% to 659 units (SEC Form 4)
- Director Gil Kristen was granted 206 shares, increasing direct ownership by 9% to 2,617 units (SEC Form 4)
- Director Garcia Paul R was granted 220 shares, increasing direct ownership by 6% to 3,906 units (SEC Form 4)